Today: 10 June 2026
Browse Category

NASDAQ:HUM 27 January 2026

Humana stock tumbles in premarket after CMS flags near-flat 2027 Medicare Advantage rates

Humana stock tumbles in premarket after CMS flags near-flat 2027 Medicare Advantage rates

Humana shares fell about 12% in premarket trading Tuesday after a U.S. proposal signaled minimal Medicare Advantage payment growth for 2027. The Centers for Medicare & Medicaid Services set a net average increase of 0.09%, citing risk score changes and new limits on chart review diagnoses. UnitedHealth and CVS Health also dropped around 9%. Investors await the April 6 final rate notice.
27 January 2026
·

Stock Market Today

  • Kalshi Co-Founder Predicts Prediction Markets Will Surpass Stock Exchanges
    June 10, 2026, 5:42 PM EDT. Kalshi co-founder and COO Luana Lopes Lara stated at Web Summit Rio on June 10, 2026, that prediction markets could become larger than traditional stock exchanges despite potential losses for participants. Prediction markets involve trading contracts based on event outcomes, differing from equity markets by focusing on future predictions rather than ownership. Lopes Lara highlighted Kalshi's readiness to collaborate closely with regulatory bodies to ensure compliance and foster growth. This outlook underscores the growing interest in alternative trading platforms challenging conventional financial markets.

Latest articles

Snap Inc. Targets Health Ad Dollars With New Snapchat Study as Pressure Builds

Snap Shares Drop Again With Tech Names Under Pressure

10 June 2026
Snap Inc. shares slid 4% to $5.38, extending a three-day losing streak and deepening doubts about its turnaround despite improved cash flow and cost cuts, as investors await CEO Evan Spiegel’s June 16 AWE keynote and weigh weak ad growth, falling eCPMs, and ongoing macro and regulatory risks.
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

10 June 2026
Outlook Therapeutics soared 26% to $0.89 on heavy volume as investors zeroed in on the FDA’s 60-day review window for Lytenava after a successful appeal, but risks remain with the stock still under $1, looming Nasdaq compliance deadlines, and warnings of possible dilution and going-concern doubts if FDA approval or favorable labeling isn’t secured soon.
Freshworks Stock Steady at $9.39 Ahead of AI Test

Freshworks Stock Steady at $9.39 Ahead of AI Test

10 June 2026
Freshworks traded flat near $9.39 on volume more than double average as investors weighed its AI-driven restructuring and Freshservice focus; with Q2 restructuring costs looming, the stock faces a key test to prove AI shifts can boost margins without hurting growth, while net dollar retention dipped to 106% and large-customer ARR rose 29%.
Go toTop